C-RLFYCasma Therapeutics
autophagy, targeted degradation, PHLYT
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-RLFY
C-RLFYC-RLFYautophagy, targeted degradation, PHLYT
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Casma Therapeutics autophagy, targeted degradation, PHLYT
Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway. Its PHLYT platform initiates target-specific autophagic degradation of disease targets independent of size or complexity. Casma aims to reprogram autophagy to eliminate diseases that current drugs have failed to target, including oncology, inflammation, neurodegeneration, and metabolic disorders.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Casma Therapeutics — Far from goals · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic